IHL — Incannex Healthcare Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- AU$65.07m
- AU$31.87m
- AU$1.38m
Australia's Incannex Healthcare gains on partnering with U.S. firm
Brief: Incannex Healthcare Posts HY Loss From Ordinary Activities A$8.5 Million
Brief: Independent Data Review Commences For Phase 2 Trial Of Psilocybin-Assisted Psychotherapy For Anxiety
Brief: Incannex Expands Intellectual Property Position Over IHL-42X
Brief: Incannex Healthcare Undertakes A$13 Million Institutional Placement
Australia's Incannex Healthcare hits 4-month low on discounted capital raise
Brief: Incannex Healthcare Seeks Trading Halt
Brief: Incannex Healthcare Says Engages Eurofins To Manufacture Renecann Therapeutic
Brief: Incannex Healthcare Says Engaged Eurofins Scientific To Manufacture Two Products
Brief: Incannex Healthcare Quarterly Activities Report And Appendix 4C Cash Flow Statement
Brief: Incannex Healthcare Completes Dosing In Phase 1 Clinical Trial To Assess Multi-Use, Anti-Inflammatory Drug Ihl-675A Proceeds To Phase 2 Clinical Trials
Brief: Incannex Healthcare Completes Positive Pre-Ind Meeting With Us FDA On Ihl-216A For Treatment Of Concussion And Traumatic Brain Injury
Brief: Incannex Healthcare Says Co Included In S&P/ASX 300 Index
Brief: Incannex Healthcare Says FY Loss From Ordinary Activities After Tax A$14.9 Mln Vs Loss A$11.4 Mln
Incannex Healthcare jumps most in about 3 yrs on acquisition
Australia's Incannex Healthcare rises on drug research deal with Curia
Brief: Incannex Healthcare Says Has Engaged Curia To Scale Up cGMP IHL-216A
Australia's Incannex rises on approval to start phase 1 clinical trial
Australia's Incannex rises on positive data from study on sleep apnoea drug